Arbutus Biopharma (ABUS) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Arbutus Biopharma (ABUS) has outperformed Gyre Therapeutics (GYRE) over the past year, losing 4.3% versus a loss of 26.7%. Over five years, ABUS leads with a +4.7% price change compared with -88.3% for GYRE. Arbutus Biopharma is the larger company by market cap ($646.8 million vs $644.7 million), about 1.0 times the size.
Gyre Therapeutics converts more of its revenue into profit, with a net margin of 8.5% versus -237.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | GYRE |
|---|---|---|
| Share price | $4.22 | $6.08 |
| Market cap | $646.82M | $644.69M |
| 1-day change | -1.63% | -5.00% |
| YTD return | -12.27% | -13.88% |
| 1-year return | -4.31% | -26.75% |
| 5-year return | +4.71% | -88.32% |
| P/E ratio (TTM) | 5.34 | — |
| Forward P/E | — | 101.33 |
| EPS (TTM) | $0.79 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | $116.59M |
| Revenue growth (YoY) | +128.21% | +10.24% |
| Net income (latest FY) | $-33.50M | $9.88M |
| Gross margin | — | 95.35% |
| Operating margin | -270.96% | 9.85% |
| Net margin | -237.88% | 8.47% |
| 52-week high | $5.45 | $9.14 |
| 52-week low | $3.50 | $5.44 |
| Distance from 52-week high | -22.57% | -33.48% |
| Analyst consensus | none | none |
| Avg. price target upside | +27.96% | +207.07% |
| Average volume | 4.81M | 110.57K |
| Shares outstanding | 153.28M | 106.03M |
| Employees | 19 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABUS has outperformed GYRE by 22.4 percentage points over the past year.
- Gyre Therapeutics is more profitable, keeping 8.5 cents of every revenue dollar as net income versus -237.9 cents for Arbutus Biopharma.
- Arbutus Biopharma grew revenue faster in its latest fiscal year (+128.21% vs +10.24%).
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
ABUS vs GYRE FAQ
Which is bigger, Arbutus Biopharma or Gyre Therapeutics?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $646.82M compared with $644.69M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, ABUS or GYRE?
ABUS returned -4.31% over the past 12 months, compared with -26.75% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.